Mayne Pharma has agreed to sell its Adelaide manufacturing plant as part of a $55 million deal to offload its international segment to Genesis Capital following pressure from shareholders to break up the company after a $672 million takeover bid collapsed last year.
Mayne Pharma will retain its core women’s health and dermatology businesses in the United States under the deal which was welcomed by investors, sending its share price up 11 per cent on Friday.
Gift articles to anyone you choose each month when you subscribe.
